Marisa Wexler, MS, senior science writer —

Psychological counseling and therapy are among the interventions that may help adults with pulmonary hypertension (PH) manage depression and anxiety, a review paper reports. Data in this area are limited, however, and the review highlighted a need for more research into how best to support the mental health…

Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…

Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…

Liqrev, a new liquid formulation of sildenafil designed for patients who have trouble swallowing tablets, is now available in the U.S., according to an announcement from CMP Pharma, its developer. Liqrev was approved by the U.S. Food and Drug Administration earlier this year as a treatment to improve…

Treatment with intravenous Revatio (sildenafil) can improve oxygen delivery and heart health in some premature babies with pulmonary hypertension, although more than four in 10 patients don’t respond to it. “Our study adds new insights on preterm and [very low birth weight]-infants with sildenafil treatment for primary early PH…

The outcomes used in clinical trials of pulmonary arterial hypertension (PAH) don’t fully reflect the priorities of patients and clinicians, a new study asserts. The study, “‘It’s that invisible illness’: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment,” was published in the journal…

Janssen Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a combination tablet containing both macitentan and tadalafil as a treatment for pulmonary arterial hypertension (PAH). “People with PAH are often prescribed numerous medicines to manage their condition, so the potential…

Treatment with AER-901, an inhaled formulation of imatinib that Aerami Therapeutics is developing as a treatment for two forms of pulmonary hypertension, was generally well-tolerated in a Phase 1 study conducted with healthy volunteers. That’s according to safety data presented by Aerami at the 2023 American Thoracic Society…

Treatment with KER-012, an experimental therapy Keros Therapeutics is developing to treat pulmonary arterial hypertension (PAH), lowered markers of heart damage, fibrosis, and inflammation in a Phase 1 clinical trial that tested the therapy in healthy postmenopausal women. Keros presented the findings at the American Thoracic Society (ATS)…

The proportion of people with pulmonary arterial hypertension (PAH) who start on a combination of medications after they’re diagnosed is low, but has increased over the last decade, a study shows. The findings were presented at the 2023 American Thoracic Society (ATS) International Conference, in the poster, “…

Gossamer Bio is planning to soon launch a Phase 3 clinical trial to test its experimental inhaled therapy seralutinib (GB002) in people with pulmonary arterial hypertension (PAH). “We remain on track to begin our Phase 3 clinical trial of seralutinib in the coming months, moving one step closer…